{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:59:25Z","timestamp":1790891965082,"version":"4.1.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"DOI":"10.1038\/s41398-024-03180-8","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:58:34Z","timestamp":1732859914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Personalized use of ketamine and esketamine for treatment-resistant depression"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-1192","authenticated-orcid":false,"given":"Gustavo C.","family":"Medeiros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Demo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6262-8264","authenticated-orcid":false,"given":"Fernando S.","family":"Goes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd D.","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"3180_CR1","unstructured":"Metrics IoH, Evaluation. Global Health Data Exchange (GHDx). Institute of Health Metrics and Evaluation, Seattle. 2021. https:\/\/www.healthdata.org\/. Accessed 15 Oct 2021."},{"key":"3180_CR2","unstructured":"WHO. Depression and other common mental disorders: global health estimates. 2017. https:\/\/www.who.int\/publications\/i\/item\/depression-global-health-estimates. Accessed 3 January 2017."},{"key":"3180_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","volume":"39","author":"PE Greenberg","year":"2021","unstructured":"Greenberg PE, Fournier A-A, Sisitsky T, Simes M, Berman R, Koenigsberg SH, et al. The economic burden of adults with major depressive disorder in the United States (2010 and 2018). Pharmacoeconomics. 2021;39:653\u201365.","journal-title":"Pharmacoeconomics"},{"key":"3180_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/da.22968","volume":"37","author":"BN Gaynes","year":"2020","unstructured":"Gaynes BN, Lux L, Gartlehner G, Asher G, Forman\u2010Hoffman V, Green J, et al. Defining treatment\u2010resistant depression. Depress Anxiety. 2020;37:134\u201345.","journal-title":"Depress Anxiety"},{"key":"3180_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/0706743719828965","volume":"64","author":"S Brown","year":"2019","unstructured":"Brown S, Rittenbach K, Cheung S, McKean G, MacMaster FP, Clement F. Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews. Can J Psychiatry. 2019;64:380\u20137.","journal-title":"Can J Psychiatry"},{"key":"3180_CR6","doi-asserted-by":"publisher","first-page":"29169","DOI":"10.4088\/JCP.20m13699","volume":"82","author":"M Zhdanava","year":"2021","unstructured":"Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J Clin Psychiatry. 2021;82:29169.","journal-title":"J Clin Psychiatry"},{"key":"3180_CR7","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1185\/03007995.2010.517716","volume":"26","author":"JI Ivanova","year":"2010","unstructured":"Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD. Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder. Curr Med Res Opin. 2010;26:2475\u201384.","journal-title":"Curr Med Res Opin"},{"key":"3180_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","volume":"267","author":"R McAllister-Williams","year":"2020","unstructured":"McAllister-Williams R, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Dis. 2020;267:264\u201382.","journal-title":"J Affect Dis"},{"key":"3180_CR9","doi-asserted-by":"crossref","unstructured":"Ionescu DF, Rosenbaum JF, Alpert JE. Pharmacological approaches to the challenge of treatment-resistant depression. Dialogues Clin Neurosci. 2022;17:111\u201326.","DOI":"10.31887\/DCNS.2015.17.2\/dionescu"},{"key":"3180_CR10","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jad.2018.04.016","volume":"235","author":"IO Bergfeld","year":"2018","unstructured":"Bergfeld IO, Mantione M, Figee M, Schuurman PR, Lok A, Denys D. Treatment-resistant depression and suicidality. J Affect Dis. 2018;235:362\u20137.","journal-title":"J Affect Dis"},{"key":"3180_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351\u20134.","journal-title":"Biol Psychiatry"},{"key":"3180_CR12","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate","year":"2006","unstructured":"Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856\u201364.","journal-title":"Arch Gen Psychiatry"},{"key":"3180_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-pharmtox-010617-052811","volume":"59","author":"TD Gould","year":"2019","unstructured":"Gould TD, Zarate CA Jr, Thompson SM. Molecular pharmacology and neurobiology of rapid-acting antidepressants. Ann Rev Pharmacol Toxicol. 2019;59:213\u201336.","journal-title":"Ann Rev Pharmacol Toxicol"},{"key":"3180_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1146\/annurev-clinpsy-072120-014126","volume":"17","author":"LM Riggs","year":"2021","unstructured":"Riggs LM, Gould TD. Ketamine and the future of rapid-acting antidepressants. Ann Rev Clin Psychol. 2021;17:207\u201331.","journal-title":"Ann Rev Clin Psychol"},{"key":"3180_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.pharmthera.2009.02.010","volume":"123","author":"R Machado-Vieira","year":"2009","unstructured":"Machado-Vieira R, Salvadore G, DiazGranados N, Zarate CA Jr. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Therap. 2009;123:143\u201350.","journal-title":"Pharmacol Therap"},{"key":"3180_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109219","volume":"218","author":"J-c Zhang","year":"2022","unstructured":"Zhang J-c, Yao W, Hashimoto K. Arketamine, a new rapid-acting antidepressant: a historical review and future directions. Neuropharmacology. 2022;218:109219.","journal-title":"Neuropharmacology"},{"key":"3180_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","volume":"75","author":"EJ Daly","year":"2018","unstructured":"Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, et al. Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2018;75:139\u201348.","journal-title":"JAMA Psychiatry"},{"key":"3180_CR18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1176\/appi.ajp.2018.17060720","volume":"175","author":"CM Canuso","year":"2018","unstructured":"Canuso CM, Singh JB, Fedgchin M, Alphs L, Lane R, Lim P, et al. Efficacy and safety of intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175:620\u201330.","journal-title":"Am J Psychiatry"},{"key":"3180_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1017\/S1092852922000293","volume":"27","author":"B Singh","year":"2022","unstructured":"Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Voort JLV. Comparative effectiveness of intravenous ketamine and intranasal esketamine in real-world setting among patients with treatment refractory depression. CNS Spectrums. 2022;27:232.","journal-title":"CNS Spectrums"},{"key":"3180_CR20","doi-asserted-by":"crossref","unstructured":"Nikayin S, Rhee TG, Cunningham ME, de Fontnouvelle CA, Ostroff RB, Sanacora G, et al. Evaluation of the trajectory of depression severity with ketamine and esketamine treatment in a Ccinical setting. JAMA Psychiatry. 2022;79:736\u201338.","DOI":"10.1001\/jamapsychiatry.2022.1074"},{"key":"3180_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jpsychires.2021.09.002","volume":"143","author":"JD Di Vincenzo","year":"2021","unstructured":"Di Vincenzo JD, Lipsitz O, Rodrigues NB, Lee Y, Gill H, Kratiuk K, et al. Ketamine monotherapy versus adjunctive ketamine in adults with treatment-resistant depression: results from the canadian rapid treatment centre of excellence. J Psychiatr Res. 2021;143:209\u201314.","journal-title":"J Psychiatr Res"},{"key":"3180_CR22","unstructured":"Administration F-TUSFaD. Spravato (Intranasal Esketamine) label. 2020."},{"key":"3180_CR23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","volume":"76","author":"KA Lapidus","year":"2014","unstructured":"Lapidus KA, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014;76:970\u20136.","journal-title":"Biol Psychiatry"},{"key":"3180_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.biopsych.2015.10.018","volume":"80","author":"JB Singh","year":"2016","unstructured":"Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, et al. Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. 2016;80:424\u201331.","journal-title":"Biol Psychiatry"},{"key":"3180_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jad.2019.11.086","volume":"264","author":"FS Correia-Melo","year":"2020","unstructured":"Correia-Melo FS, Leal GC, Vieira F, Jesus-Nunes AP, Mello RP, Magnavita G, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Dis. 2020;264:527\u201334.","journal-title":"J Affect Dis"},{"key":"3180_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/acps.12572","volume":"134","author":"CK Loo","year":"2016","unstructured":"Loo CK, G\u00e1lvez V, O\u2019Keefe E, Mitchell PB, Hadzi\u2010Pavlovic D, Leyden J, et al. Placebo\u2010controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatrica Scandinavica. 2016;134:48\u201356.","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"3180_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.513068","volume":"12","author":"VB Cavenaghi","year":"2021","unstructured":"Cavenaghi VB, Da Costa LP, Lacerda ALT, Hirata ES, Miguel EC, Fraguas R. Subcutaneous ketamine in depression: a systematic review. Frontiers in Psychiatry. 2021;12:513068.","journal-title":"Frontiers in Psychiatry"},{"key":"3180_CR28","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.jagp.2017.06.007","volume":"25","author":"D George","year":"2017","unstructured":"George D, G\u00e1lvez V, Martin D, Kumar D, Leyden J, Hadzi-Pavlovic D, et al. Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. Am J Geriatric Psychiatry. 2017;25:1199\u2013209.","journal-title":"Am J Geriatric Psychiatry"},{"key":"3180_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jad.2024.09.141","volume":"369","author":"F Palhano-Fontes","year":"2024","unstructured":"Palhano-Fontes F, Cavalcanti-Ribeiro P, da Costa Gon\u00e7alves KT, de Almeida VRN, Barbosa DC, de Ara\u00fajo Ferreira MA, et al. Repeated subcutaneous esketamine on treatment-resistant depression: An open-label dose titration study. J Affect Disord. 2024;369:155\u201363.","journal-title":"J Affect Disord"},{"key":"3180_CR30","doi-asserted-by":"crossref","unstructured":"Meshkat S, Haikazian S, Di Vincenzo JD, Fancy F, Johnson D, Chen-Li D, et al. Oral ketamine for depression: an updated systematic review. World J Biol Psychiatry. 2023;24:545\u201357.","DOI":"10.1080\/15622975.2023.2169349"},{"key":"3180_CR31","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev-genom-082410-101446","volume":"12","author":"IS Chan","year":"2011","unstructured":"Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu Rev Genomics Hum Genet. 2011;12:217\u201344.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"3180_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1056\/NEJMp1500523","volume":"372","author":"FS Collins","year":"2015","unstructured":"Collins FS, Varmus H. A new initiative on precision medicine. New Engl J Med. 2015;372:793\u20135.","journal-title":"New Engl J Med"},{"key":"3180_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1093\/schbul\/sbaa120","volume":"47","author":"G Salazar de Pablo","year":"2021","unstructured":"Salazar de Pablo G, Studerus E, Vaquerizo-Serrano J, Irving J, Catalan A, Oliver D, et al. Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice. Schizophrenia Bull. 2021;47:284\u201397.","journal-title":"Schizophrenia Bull"},{"key":"3180_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-statistics-030718-105251","volume":"6","author":"MR Kosorok","year":"2019","unstructured":"Kosorok MR, Laber EB. Precision medicine. Annu Review Stat Appl. 2019;6:263\u201386.","journal-title":"Annu Review Stat Appl"},{"key":"3180_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Roudaia L, Buhlaiga N, Del Rincon S, Papneja N, Miller W. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27:87\u201397.","journal-title":"Curr Oncol"},{"key":"3180_CR36","doi-asserted-by":"publisher","first-page":"lgz008","DOI":"10.1093\/jncimonographs\/lgz008","volume":"2019","author":"DM Keefe","year":"2019","unstructured":"Keefe DM, Bateman EH. Potential successes and challenges of targeted cancer therapies. JNCI Monographs. 2019;2019:lgz008.","journal-title":"JNCI Monographs"},{"key":"3180_CR37","doi-asserted-by":"crossref","unstructured":"Bzdok D, Varoquaux G, Steyerberg EW. Prediction, not association, paves the road to precision medicine. JAMA Psychiatry. 2020;78:127\u201328.","DOI":"10.1001\/jamapsychiatry.2020.2549"},{"key":"3180_CR38","first-page":"223","volume":"3","author":"D Bzdok","year":"2018","unstructured":"Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3:223\u201330.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"3180_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurpub\/ckv190","volume":"26","author":"M Devaux","year":"2016","unstructured":"Devaux M, Sassi F. Social disparities in hazardous alcohol use: self-report bias may lead to incorrect estimates. Eur J Public Health. 2016;26:129\u201334.","journal-title":"Eur J Public Health"},{"key":"3180_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1590\/1516-4446-2015-1680","volume":"38","author":"GC Medeiros","year":"2016","unstructured":"Medeiros GC, Sen\u00e7o SB, Lafer B, Almeida KM. Association between duration of untreated bipolar disorder and clinical outcome: data from a Brazilian sample. Brazilian J Psychiatry. 2016;38:6\u201310.","journal-title":"Brazilian J Psychiatry"},{"key":"3180_CR41","doi-asserted-by":"crossref","unstructured":"Medeiros GC, Gould TD, Prueitt WL, Nanavati J, Grunebaum MF, Farber NB, et al. Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis. Mol Psychiatry. 2022;27:3658\u201369.","DOI":"10.1038\/s41380-022-01652-1"},{"key":"3180_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113412","volume":"293","author":"GC Medeiros","year":"2020","unstructured":"Medeiros GC, Prueitt WL, Minhajuddin A, Patel SS, Czysz AH, Furman JL, et al. Childhood maltreatment and impact on clinical features of major depression in adults. Psychiatry Res. 2020;293:113412.","journal-title":"Psychiatry Res"},{"key":"3180_CR43","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/COH.0b013e32833ed177","volume":"5","author":"K Strimbu","year":"2010","unstructured":"Strimbu K, Tavel JA. What are biomarkers? Curr Opin HIV AIDS. 2010;5:463.","journal-title":"Curr Opin HIV AIDS"},{"key":"3180_CR44","unstructured":"Group F-NBW. BEST (Biomarkers, endpoints, and other tools) resource [Internet]. 2016. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK326791\/."},{"key":"3180_CR45","doi-asserted-by":"crossref","unstructured":"Moriarity DP, Alloy LB. Back to basics: the importance of measurement properties in biological psychiatry. Neurosci Biobehav Rev. 2021;123:72\u201382.","DOI":"10.1016\/j.neubiorev.2021.01.008"},{"key":"3180_CR46","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/23743603.2019.1684822","volume":"3","author":"F Anvari","year":"2018","unstructured":"Anvari F, Lakens D. The replicability crisis and public trust in psychological science. Compr Results Soc Psychol. 2018;3:266\u201386.","journal-title":"Compr Results Soc Psychol"},{"key":"3180_CR47","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.biopsych.2022.12.020","volume":"93","author":"LR Brucar","year":"2023","unstructured":"Brucar LR, Feczko E, Fair DA, Zilverstand A. Current approaches in computational psychiatry for the data-driven identification of brain-based subtypes. Biol Psychiatry. 2023;93:704\u201316.","journal-title":"Biol Psychiatry"},{"key":"3180_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1535370217750088","volume":"243","author":"RM Califf","year":"2018","unstructured":"Califf RM. Biomarker definitions and their applications. Exp Biol Med. 2018;243:213\u201321.","journal-title":"Exp Biol Med"},{"key":"3180_CR49","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jalz.2016.09.014","volume":"13","author":"SE O\u2019Bryant","year":"2017","unstructured":"O\u2019Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, et al. Blood-based biomarkers in Alzheimer disease: current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. Alzheimer\u2019s Dementia. 2017;13:45\u201358.","journal-title":"Alzheimer\u2019s Dementia"},{"key":"3180_CR50","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pnpbp.2013.09.017","volume":"48","author":"AL Lopresti","year":"2014","unstructured":"Lopresti AL, Maker GL, Hood SD, Drummond PD. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog Neuro Psychopharmacol Biol Psychiatry. 2014;48:102\u201311.","journal-title":"Prog Neuro Psychopharmacol Biol Psychiatry"},{"key":"3180_CR51","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jad.2018.09.067","volume":"243","author":"K Perlman","year":"2019","unstructured":"Perlman K, Benrimoh D, Israel S, Rollins C, Brown E, Tunteng J-F, et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder. J Affect Dis. 2019;243:503\u201315.","journal-title":"J Affect Dis"},{"key":"3180_CR52","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1176\/appi.ajp.160.4.636","volume":"160","author":"II Gottesman","year":"2003","unstructured":"Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J. Psychiatry. 2003;160:636\u201345.","journal-title":"Am J. Psychiatry"},{"key":"3180_CR53","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1601-183X.2005.00186.x","volume":"5","author":"TD Gould","year":"2006","unstructured":"Gould TD, Gottesman II. Psychiatric endophenotypes and the development of valid animal models. Genes Brain Behav. 2006;5:113\u20139.","journal-title":"Genes Brain Behav"},{"key":"3180_CR54","first-page":"250","volume":"27","author":"RM Bagby","year":"2002","unstructured":"Bagby RM, Ryder AG, Cristi C. Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci. 2002;27:250\u20137.","journal-title":"J Psychiatry Neurosci"},{"key":"3180_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115165","volume":"323","author":"I Turkoz","year":"2023","unstructured":"Turkoz I, Nelson JC, Wilkinson ST, Borentain S, Macaluso M, Trivedi MH, et al. Predictors of response and remission in patients with treatment-resistant depression: a post hoc pooled analysis of two acute trials of esketamine nasal spray. Psychiatry Res. 2023;323:115165.","journal-title":"Psychiatry Res"},{"key":"3180_CR56","doi-asserted-by":"crossref","unstructured":"Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry. 2015;76:1374\u201384.","DOI":"10.4088\/JCP.14r09528"},{"key":"3180_CR57","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jad.2017.10.008","volume":"227","author":"C Tunvirachaisakul","year":"2018","unstructured":"Tunvirachaisakul C, Gould RL, Coulson MC, Ward EV, Reynolds G, Gathercole RL, et al. Predictors of treatment outcome in depression in later life: a systematic review and meta-analysis. J Affect Dis. 2018;227:164\u201382.","journal-title":"J Affect Dis"},{"key":"3180_CR58","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0269881120978398","volume":"35","author":"AC Lucchese","year":"2021","unstructured":"Lucchese AC, Sarin LM, Magalh\u00e3es EJM, Del Sant LC, B Puertas C, Tuena MA, et al. Repeated subcutaneous esketamine for treatment-resistant depression: impact of the degree of treatment resistance and anxiety comorbidity. J Psychopharmacol. 2021;35:142\u20139.","journal-title":"J Psychopharmacol"},{"key":"3180_CR59","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/S0893-133X(01)00271-8","volume":"25","author":"HA Sackeim","year":"2001","unstructured":"Sackeim HA, Rush AJ, George MS, Marangell LB, Husain MM, Nahas Z, et al. Vagus nerve stimulation (VNS\u2122) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713\u201328.","journal-title":"Neuropsychopharmacology"},{"key":"3180_CR60","doi-asserted-by":"crossref","unstructured":"Jesus\u2010Nunes AP, Leal GC, Correia\u2010Melo FS, Vieira F, Mello RP, Caliman\u2010Fontes AT, et al. Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment\u2010resistant depression. Hum Psychopharmacol Clin Exp. 2022;37:e2836.","DOI":"10.1002\/hup.2836"},{"key":"3180_CR61","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jad.2009.04.014","volume":"120","author":"A Tadi\u0107","year":"2010","unstructured":"Tadi\u0107 A, Helmreich I, Mergl R, Hautzinger M, Kohnen R, Henkel V, et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J Affect Dis. 2010;120:86\u201393.","journal-title":"J Affect Dis"},{"key":"3180_CR62","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.nbd.2012.05.008","volume":"52","author":"CH Fu","year":"2013","unstructured":"Fu CH, Steiner H, Costafreda SG. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol Dis. 2013;52:75\u201383.","journal-title":"Neurobiol Dis"},{"key":"3180_CR63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-01122-8","volume":"10","author":"VJ Sydnor","year":"2020","unstructured":"Sydnor VJ, Lyall AE, Cetin-Karayumak S, Cheung JC, Felicione JM, Akeju O, et al. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine\u2019s antidepressant effects. Trans Psychiatry. 2020;10:1\u201310.","journal-title":"Trans Psychiatry"},{"key":"3180_CR64","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jad.2015.11.018","volume":"190","author":"MM Vasavada","year":"2016","unstructured":"Vasavada MM, Leaver AM, Espinoza RT, Joshi SH, Njau SN, Woods RP, et al. Structural connectivity and response to ketamine therapy in major depression: a preliminary study. J Affect Dis. 2016;190:836\u201341.","journal-title":"J Affect Dis"},{"key":"3180_CR65","first-page":"913","volume":"4","author":"AD Davis","year":"2019","unstructured":"Davis AD, Hassel S, Arnott SR, Harris J, Lam RW, Milev R, et al. White matter indices of medication response in major depression: a diffusion tensor imaging study. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;4:913\u201324.","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"3180_CR66","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1192\/bjp.bp.113.140376","volume":"205","author":"MS Korgaonkar","year":"2014","unstructured":"Korgaonkar MS, Williams LM, Song YJ, Usherwood T, Grieve SM. Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder. Br J Psychiatry. 2014;205:321\u20138.","journal-title":"Br J Psychiatry"},{"key":"3180_CR67","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ebiom.2014.12.002","volume":"2","author":"MS Korgaonkar","year":"2015","unstructured":"Korgaonkar MS, Rekshan W, Gordon E, Rush AJ, Williams LM, Blasey C, et al. Magnetic resonance imaging measures of brain structure to predict antidepressant treatment outcome in major depressive disorder. EBioMedicine. 2015;2:37\u201345.","journal-title":"EBioMedicine"},{"key":"3180_CR68","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.biopsych.2008.09.029","volume":"65","author":"LE Phelps","year":"2009","unstructured":"Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate JrCA. Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry. 2009;65:181\u20134.","journal-title":"Biol Psychiatry"},{"key":"3180_CR69","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.4088\/JCP.08m04659","volume":"70","author":"R Machado-Vieira","year":"2009","unstructured":"Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, et al. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry. 2009;70:1662.","journal-title":"J Clin Psychiatry"},{"key":"3180_CR70","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.biopsych.2008.08.014","volume":"65","author":"G Salvadore","year":"2009","unstructured":"Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate JrCA, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry. 2009;65:289\u201395.","journal-title":"Biol Psychiatry"},{"key":"3180_CR71","doi-asserted-by":"crossref","unstructured":"Medeiros GC, Matheson M, Demo I, Reid MJ, Matheson S, Twose C, et al. Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies. Lancet Psychiatry. 2023;10:790\u2013800.","DOI":"10.1016\/S2215-0366(23)00183-9"},{"key":"3180_CR72","doi-asserted-by":"crossref","unstructured":"W\u0142odarczyk A, Cuba\u0142a WJ, Ga\u0142uszko-W\u0119gielnik M, Szarmach J. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. Medicine. 2021;100:e26769.","DOI":"10.1097\/MD.0000000000026769"},{"key":"3180_CR73","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","volume":"25","author":"M Fava","year":"2020","unstructured":"Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020;25:1592\u2013603.","journal-title":"Mol Psychiatry"},{"key":"3180_CR74","first-page":"10121","volume":"76","author":"L-B Wan","year":"2014","unstructured":"Wan L-B, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2014;76:10121.","journal-title":"J Clin Psychiatry"},{"key":"3180_CR75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.pscychresns.2010.10.009","volume":"191","author":"GW Valentine","year":"2011","unstructured":"Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, et al. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Res Neuroimaging. 2011;191:122\u20137.","journal-title":"Psychiatry Res Neuroimaging"},{"key":"3180_CR76","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jad.2014.02.017","volume":"159","author":"DA Luckenbaugh","year":"2014","unstructured":"Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Dis. 2014;159:56\u201361.","journal-title":"J Affect Dis"},{"key":"3180_CR77","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","volume":"176","author":"JL Phillips","year":"2019","unstructured":"Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial. Am J Psychiatry. 2019;176:401\u20139.","journal-title":"Am J Psychiatry"},{"key":"3180_CR78","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1177\/0269881118793104","volume":"32","author":"RK Thomas","year":"2018","unstructured":"Thomas RK, Baker G, Lind J, Dursun S. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness. J Psychopharmacol. 2018;32:1110\u20137.","journal-title":"J Psychopharmacol"},{"key":"3180_CR79","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3389\/fpsyt.2020.00844","volume":"11","author":"V Andrashko","year":"2020","unstructured":"Andrashko V, Novak T, Brunovsky M, Klirova M, Sos P, Horacek J. The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Front Psychiatry. 2020;11:844.","journal-title":"Front Psychiatry"},{"key":"3180_CR80","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/bdi.12277","volume":"17","author":"DF Ionescu","year":"2015","unstructured":"Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Zarate JrCA. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Dis. 2015;17:438\u201343.","journal-title":"Bipolar Dis"},{"key":"3180_CR81","doi-asserted-by":"publisher","first-page":"5470","DOI":"10.4088\/JCP.14m09049","volume":"75","author":"DF Ionescu","year":"2014","unstructured":"Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Voort JLV, et al. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014;75:5470.","journal-title":"J Clin Psychiatry"},{"key":"3180_CR82","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jpsychires.2018.09.013","volume":"106","author":"W Zheng","year":"2018","unstructured":"Zheng W, Zhou Y-L, Liu W-J, Wang C-Y, Zhan Y-N, Li H-Q, et al. Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression. J psychiatric Res. 2018;106:61\u20138.","journal-title":"J psychiatric Res"},{"key":"3180_CR83","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jad.2020.06.020","volume":"275","author":"W Zheng","year":"2020","unstructured":"Zheng W, Zhou Y-L, Liu W-J, Wang C-Y, Zhan Y-N, Lan X-F, et al. A preliminary study of adjunctive ketamine for treatment-resistant bipolar depression. J Affect Dis. 2020;275:38\u201343.","journal-title":"J Affect Dis"},{"key":"3180_CR84","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.euroneuro.2019.02.005","volume":"29","author":"S Aust","year":"2019","unstructured":"Aust S, G\u00e4rtner M, Basso L, Otte C, Wingenfeld K, Chae WR, et al. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder. Eur Neuropsychopharmacol. 2019;29:529\u201338.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3180_CR85","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/acps.13096","volume":"140","author":"C Wang","year":"2019","unstructured":"Wang C, Zhou Y, Zheng W, Liu W, Zhan Y, Li H, et al. Association between depression subtypes and response to repeated\u2010dose intravenous ketamine. Acta Psychiatrica Scandinavica. 2019;140:446\u201357.","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"3180_CR86","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jad.2018.02.049","volume":"232","author":"MJ Niciu","year":"2018","unstructured":"Niciu MJ, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Dis. 2018;232:310\u20135.","journal-title":"J Affect Dis"},{"key":"3180_CR87","doi-asserted-by":"publisher","first-page":"e417","DOI":"10.4088\/JCP.13m08698","volume":"75","author":"MJ Niciu","year":"2014","unstructured":"Niciu MJ, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, et al. Clinical predictors of ketamine response in treatment-resistant major depression. J Clinical Psychiatry. 2014;75:e417.","journal-title":"J Clinical Psychiatry"},{"key":"3180_CR88","doi-asserted-by":"publisher","first-page":"35","DOI":"10.12740\/PP\/21175","volume":"48","author":"A Permoda-Osip","year":"2014","unstructured":"Permoda-Osip A, Skibinska M, Bartkowska-Sniatkowska A, Kliwicki S, Chlopocka-Wozniak M, Rybakowski JK. Factors connected with efficacy of single ketamine infusion in bipolar depression. Psychiatr Pol. 2014;48:35\u201347.","journal-title":"Psychiatr Pol"},{"key":"3180_CR89","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/JCP.0000000000001209","volume":"40","author":"MP Freeman","year":"2020","unstructured":"Freeman MP, Hock RS, Papakostas GI, Judge H, Cusin C, Mathew SJ, et al. Body mass index as a moderator of treatment response to ketamine for major depressive disorder. J Clin Psychopharmacol. 2020;40:287.","journal-title":"J Clin Psychopharmacol"},{"key":"3180_CR90","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/ph12030133","volume":"12","author":"B O\u2019Brien","year":"2019","unstructured":"O\u2019Brien B, Lijffijt M, Wells A, Swann AC, Mathew SJ. The impact of childhood maltreatment on intravenous ketamine outcomes for adult patients with treatment-resistant depression. Pharmaceuticals. 2019;12:133.","journal-title":"Pharmaceuticals"},{"key":"3180_CR91","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jad.2022.10.031","volume":"321","author":"B O\u2019Brien","year":"2023","unstructured":"O\u2019Brien B, Lee J, Kim S, Nandra GS, Pannu P, Swann AC, et al. Replication of distinct trajectories of antidepressant response to intravenous ketamine. J Affect Dis. 2023;321:140\u20136.","journal-title":"J Affect Dis"},{"key":"3180_CR92","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/JCP.0000000000001149","volume":"40","author":"RM Dale","year":"2020","unstructured":"Dale RM, Bryant KA, Thompson NR. Metabolic syndrome rather than body mass index is associated with treatment response to ketamine infusions. J Clin Psychopharmacol. 2020;40:75\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"3180_CR93","doi-asserted-by":"crossref","unstructured":"Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: in search of clinical moderators. Mol Psychiatry. 2022;27:5096\u2013112.","DOI":"10.1038\/s41380-022-01757-7"},{"key":"3180_CR94","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/npr2.12165","volume":"41","author":"T Nakamura","year":"2021","unstructured":"Nakamura T, Tomita M, Horikawa N, Ishibashi M, Uematsu K, Hiraki T, et al. Functional connectivity between the amygdala and subgenual cingulate gyrus predicts the antidepressant effects of ketamine in patients with treatment\u2010resistant depression. Neuropsychopharmacol Rep. 2021;41:168\u201378.","journal-title":"Neuropsychopharmacol Rep"},{"key":"3180_CR95","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1017\/S1092852920002102","volume":"27","author":"O Lipsitz","year":"2022","unstructured":"Lipsitz O, McIntyre RS, Rodrigues NB, Lee Y, Gill H, Subramaniapillai M, et al. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? results from the Canadian rapid treatment center of excellence. CNS Spectrums. 2022;27:322\u201330.","journal-title":"CNS Spectrums"},{"key":"3180_CR96","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3390\/ph14050430","volume":"14","author":"N G\u00f3rska","year":"2021","unstructured":"G\u00f3rska N, Cuba\u0142a WJ, S\u0142upski J, Wiglusz MS, Ga\u0142uszko-W\u0119gielnik M, Kawka M, et al. Magnesium in ketamine administration in treatment-resistant depression. Pharmaceuticals. 2021;14:430.","journal-title":"Pharmaceuticals"},{"key":"3180_CR97","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000457960","volume":"86","author":"ST Wilkinson","year":"2017","unstructured":"Wilkinson ST, Wright D, Fasula MK, Fenton L, Griepp M, Ostroff RB, et al. Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychother Psychosomatics. 2017;86:162\u20137.","journal-title":"Psychother Psychosomatics"},{"key":"3180_CR98","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1177\/0004867416631828","volume":"51","author":"C Cusin","year":"2017","unstructured":"Cusin C, Ionescu DF, Pavone KJ, Akeju O, Cassano P, Taylor N, et al. Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry. 2017;51:55\u201364.","journal-title":"Aust N Z J Psychiatry"},{"key":"3180_CR99","doi-asserted-by":"crossref","unstructured":"Abbar M, Demattei C, El-Hage W, Llorca P-M, Samalin L, Demaricourt P, et al. Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial. BMJ. 2022;376:e067194.","DOI":"10.1136\/bmj-2021-067194"},{"key":"3180_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-020-01158-w","volume":"11","author":"JL Kruse","year":"2021","unstructured":"Kruse JL, Vasavada MM, Olmstead R, Hellemann G, Wade B, Breen EC, et al. Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers. Trans Psychiatry. 2021;11:1\u20139.","journal-title":"Trans Psychiatry"},{"key":"3180_CR101","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/13651501.2017.1297834","volume":"21","author":"JK Rybakowski","year":"2017","unstructured":"Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska A. Ketamine augmentation rapidly improves depression scores in inpatients with treatment-resistant bipolar depression. Int J Psychiatry Clin Practice. 2017;21:99\u2013103.","journal-title":"Int J Psychiatry Clin Practice"},{"key":"3180_CR102","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.biopsych.2012.03.029","volume":"72","author":"BR Cornwell","year":"2012","unstructured":"Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry. 2012;72:555\u201361.","journal-title":"Biol Psychiatry"},{"key":"3180_CR103","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpsychires.2019.01.010","volume":"110","author":"MP Freeman","year":"2019","unstructured":"Freeman MP, Papakostas GI, Hoeppner B, Mazzone E, Judge H, Cusin C, et al. Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. J Psychiatr Res. 2019;110:166\u201371.","journal-title":"J Psychiatr Res"},{"key":"3180_CR104","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jad.2020.11.011","volume":"280","author":"GC Medeiros","year":"2021","unstructured":"Medeiros GC, Greenstein D, Kadriu B, Yuan P, Park LT, Gould TD, et al. Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. J Affect Disord. 2021;280:136\u20139.","journal-title":"J Affect Disord"},{"key":"3180_CR105","doi-asserted-by":"crossref","unstructured":"G\u00f3rska N, Cuba\u0142a WJ, S\u0142upski J, Wiglusz MS, Ga\u0142uszko-W\u0119gielnik M, Kawka M, et al. Magnesium in ketamine administration in treatment-resistant depression. Pharmaceuticals (Basel). 2021;14:430.","DOI":"10.3390\/ph14050430"},{"key":"3180_CR106","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/JCP.0000000000000316","volume":"35","author":"MA Frye","year":"2015","unstructured":"Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol. 2015;35:334\u20136.","journal-title":"J Clin Psychopharmacol"},{"key":"3180_CR107","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.4088\/JCP.16l11277","volume":"78","author":"CS Albott","year":"2017","unstructured":"Albott CS, Shiroma PR, Cullen KR, Johns B, Thuras P, Wels J, et al. The antidepressant effect of repeat dose intravenous ketamine Is delayed by concurrent benzodiazepine use. J Clin Psychiatry. 2017;78:e308\u2013e9.","journal-title":"J Clin Psychiatry"},{"key":"3180_CR108","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","volume":"175","author":"NR Williams","year":"2018","unstructured":"Williams NR, Heifets BD, Blasey C, Sudheimer K, Pannu J, Pankow H, et al. Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry. 2018;175:1205\u201315.","journal-title":"Am J Psychiatry"},{"key":"3180_CR109","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1016\/j.biopsych.2019.02.008","volume":"85","author":"T Marton","year":"2019","unstructured":"Marton T, Barnes DE, Wallace A, Woolley JD. Concurrent use of buprenorphine, methadone, or naltrexone does not inhibit ketamine\u2019s antidepressant activity. Biol Psychiatry. 2019;85:e75\u2013e6.","journal-title":"Biol Psychiatry"},{"key":"3180_CR110","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/jamapsychiatry.2018.3990","volume":"76","author":"G Yoon","year":"2019","unstructured":"Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA Psychiatry. 2019;76:337\u20138.","journal-title":"JAMA Psychiatry"},{"key":"3180_CR111","doi-asserted-by":"publisher","first-page":"e555","DOI":"10.4088\/JCP.17f11629","volume":"78","author":"C Andrade","year":"2017","unstructured":"Andrade C. Ketamine for depression, 2: diagnostic and contextual indications. J Clin Psychiatry. 2017;78:e555\u2013e8.","journal-title":"J Clin Psychiatry"},{"key":"3180_CR112","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793\u2013802.","journal-title":"Arch Gen Psychiatry"},{"key":"3180_CR113","doi-asserted-by":"publisher","first-page":"858251","DOI":"10.1155\/2015\/858251","volume":"2015","author":"AJ Xu","year":"2015","unstructured":"Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, et al. Lithium and valproate levels do not correlate with ketamine\u2019s antidepressant efficacy in treatment-resistant bipolar depression. Neural Plast. 2015;2015:858251.","journal-title":"Neural Plast"},{"key":"3180_CR114","doi-asserted-by":"crossref","unstructured":"Yonezawa K, Uchida H, Yatomi T, Ohtani Y, Nomoto-Takahashi K, Nakajima S, et al. Factors associated with antidepressant effects of ketamine: a reanalysis of double-blind randomized placebo-controlled trial of intravenous ketamine for treatment-resistant depression. Pharmacopsychiatry. 2023;57:35\u201340.","DOI":"10.1055\/a-2179-8884"},{"key":"3180_CR115","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jad.2017.09.023","volume":"227","author":"GI van Schalkwyk","year":"2018","unstructured":"van Schalkwyk GI, Wilkinson ST, Davidson L, Silverman WK, Sanacora G. Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: analysis of the clinician administered dissociative state scale. J Affect Dis. 2018;227:11\u20136.","journal-title":"J Affect Dis"},{"key":"3180_CR116","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jad.2019.12.023","volume":"264","author":"DS Mathai","year":"2020","unstructured":"Mathai DS, Meyer MJ, Storch EA, Kosten TR. The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: a systematic review. J Affect Dis. 2020;264:123\u20139.","journal-title":"J Affect Dis"},{"key":"3180_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20190-4","volume":"11","author":"ED Ballard","year":"2020","unstructured":"Ballard ED, Zarate JrCA. The role of dissociation in ketamine\u2019s antidepressant effects. Nat Commun. 2020;11:6431.","journal-title":"Nat Commun"},{"key":"3180_CR118","doi-asserted-by":"publisher","first-page":"8100","DOI":"10.4088\/JCP.20m13232","volume":"81","author":"M-H Chen","year":"2020","unstructured":"Chen M-H, Lin W-C, Wu H-J, Bai Y-M, Li C-T, Tsai S-J, et al. Happiness during low-dose ketamine infusion predicts treatment response: reexploring the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. J Clin Psychiatry. 2020;81:8100.","journal-title":"J Clin Psychiatry"},{"key":"3180_CR119","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/JCP.0000000000001542","volume":"42","author":"KM Keith","year":"2022","unstructured":"Keith KM, Geller J, Froehlich A, Arfken C, Oxley M, Mischel N. Vital sign changes during intravenous ketamine infusions for depression: an exploratory study of prognostic indications. J Clin Psychopharmacol. 2022;42:254\u20139.","journal-title":"J Clin Psychopharmacol"},{"key":"3180_CR120","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0033-1349861","volume":"46","author":"A Permoda-Osip","year":"2013","unstructured":"Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A, Chlopocka-Wozniak M, Rybakowski JK. Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression. Pharmacopsychiatry. 2013;46:227\u20138.","journal-title":"Pharmacopsychiatry"},{"key":"3180_CR121","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1055\/s-0034-1377042","volume":"47","author":"NB Lundin","year":"2014","unstructured":"Lundin NB, Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, et al. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry. 2014;47:141\u20134.","journal-title":"Pharmacopsychiatry"},{"key":"3180_CR122","doi-asserted-by":"crossref","unstructured":"Farmer CA, Gilbert JR, Moaddel R, George J, Adeojo L, Lovett J, et al. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology. 2020;45:1398\u2013404.","DOI":"10.1038\/s41386-020-0663-6"},{"key":"3180_CR123","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jpsychires.2019.08.005","volume":"117","author":"MF Grunebaum","year":"2019","unstructured":"Grunebaum MF, Galfalvy HC, Choo TH, Parris MS, Burke AK, Suckow RF, et al. Ketamine metabolite pilot study in a suicidal depression trial. J Psychiatr Res. 2019;117:129\u201334.","journal-title":"J Psychiatr Res"},{"key":"3180_CR124","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature17998","volume":"533","author":"P Zanos","year":"2016","unstructured":"Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481\u20136.","journal-title":"Nature"},{"key":"3180_CR125","doi-asserted-by":"crossref","unstructured":"Paul RK, Singh NS, Khadeer M, Moaddel R, Sanghvi M, Green CE, et al. (R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function. Anesthesiology. 2014;121:149\u201359.","DOI":"10.1097\/ALN.0000000000000285"},{"key":"3180_CR126","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1007\/s00213-023-06480-x","volume":"240","author":"M Dutton","year":"2023","unstructured":"Dutton M, Can AT, Lagopoulos J, Hermens DF. Oral ketamine may offer a solution to the ketamine conundrum. Psychopharmacology (Berl). 2023;240:2483\u201397.","journal-title":"Psychopharmacology (Berl)"},{"key":"3180_CR127","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1038\/npp.2017.94","volume":"42","author":"TP Su","year":"2017","unstructured":"Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, et al. Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42:2482\u201392.","journal-title":"Neuropsychopharmacology"},{"key":"3180_CR128","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/npp.2011.338","volume":"37","author":"L Ibrahim","year":"2012","unstructured":"Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4\u2009week, double-blind, placebo-controlled study. Neuropsychopharmacology. 2012;37:1526\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"3180_CR129","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.biopsych.2012.03.004","volume":"72","author":"CA Zarate","year":"2012","unstructured":"Zarate CA, Brutsche N, Laje G, Luckenbaugh DA, Venkata SL, Ramamoorthy A, et al. Relationship of ketamine\u2019s plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry. 2012;72:331\u20138.","journal-title":"Biol Psychiatry"},{"key":"3180_CR130","doi-asserted-by":"publisher","unstructured":"Murrough JW, Wan LB, Iacoviello B, Collins KA, Solon C, Glicksberg B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl). 2013;11: https:\/\/doi.org\/10.1007\/s00213-013-3255-x.","DOI":"10.1007\/s00213-013-3255-x"},{"key":"3180_CR131","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1017\/S1461145714001011","volume":"17","author":"PR Shiroma","year":"2014","unstructured":"Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17:1805\u201313.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3180_CR132","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/bdi.12487","volume":"19","author":"MF Grunebaum","year":"2017","unstructured":"Grunebaum MF, Ellis SP, Keilp JG, Moitra VK, Cooper TB, Marver JE, et al. Ketamine versus midazolam in bipolar depression with suicidal thoughts: A pilot midazolam-controlled randomized clinical trial. Bipolar Disord. 2017;19:176\u201383.","journal-title":"Bipolar Disord"},{"key":"3180_CR133","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jad.2020.08.058","volume":"277","author":"PR Shiroma","year":"2020","unstructured":"Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S, et al. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2020;277:470\u20137.","journal-title":"J Affect Disord"},{"key":"3180_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-03789-3","volume":"22","author":"D Dai","year":"2022","unstructured":"Dai D, Miller C, Valdivia V, Boyle B, Bolton P, Li S, et al. Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review. BMC Psychiatry. 2022;22:140.","journal-title":"BMC Psychiatry"},{"key":"3180_CR135","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jad.2023.04.015","volume":"333","author":"A Zavaliangos-Petropulu","year":"2023","unstructured":"Zavaliangos-Petropulu A, McClintock SM, Khalil J, Joshi SH, Taraku B, Al-Sharif NB, et al. Neurocognitive effects of subanesthetic serial ketamine infusions in treatment resistant depression. J Affect Disord. 2023;333:161\u201371.","journal-title":"J Affect Disord"},{"key":"3180_CR136","doi-asserted-by":"publisher","first-page":"115829","DOI":"10.1016\/j.psychres.2024.115829","volume":"335","author":"B Singh","year":"2024","unstructured":"Singh B, Parikh SV, Voort JLV, Pazdernik VK, Achtyes ED, Goes FS, et al. Change in neurocognitive functioning in patients with treatment-resistant depression with serial intravenous ketamine infusions: the Bio-K multicenter trial. Psychiatry Res. 2024;335:115829.","journal-title":"Psychiatry Res"},{"key":"3180_CR137","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1176\/appi.neuropsych.14100243","volume":"27","author":"PR Shiroma","year":"2015","unstructured":"Shiroma PR, Albott CS, Johns B, Thuras P, Wels J, Lim KO. The effect of repeated ketamine infusion over facial emotion recognition in treatment-resistant depression: a peliminary report. J Neuropsychiatry Clin Neurosci. 2015;27:362\u20134.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"3180_CR138","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jad.2018.12.005","volume":"246","author":"W Zheng","year":"2019","unstructured":"Zheng W, Zhou YL, Liu WJ, Wang CY, Zhan YN, Li HQ, et al. Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder. J Affect Disord. 2019;246:241\u20137.","journal-title":"J Affect Disord"},{"key":"3180_CR139","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1093\/ijnp\/pyac045","volume":"25","author":"JL Phillips","year":"2022","unstructured":"Phillips JL, Van Geel A, Burhunduli P, Vasudev D, Batten LA, Norris S, et al. Assessment of objective and subjective cognitive function in patients with treatment-resistant depression undergoing repeated ketamine infusions. Int J Neuropsychopharmacol. 2022;25:992\u20131002.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3180_CR140","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jad.2022.09.043","volume":"319","author":"G Martinotti","year":"2022","unstructured":"Martinotti G, Vita A, Fagiolini A, Maina G, Bertolino A, Dell\u2019Osso B, et al. Real-world experience of esketamine use to manage treatment-resistant depression: a multicentric study on safety and effectiveness (REAL-ESK study). J Affect Dis. 2022;319:646\u201354.","journal-title":"J Affect Dis"},{"key":"3180_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.608499","volume":"12","author":"EJM Magalh\u00e3es","year":"2021","unstructured":"Magalh\u00e3es EJM, Sarin LM, Del Sant LC, Lucchese AC, Nakahira C, Tuena MA, et al. A clinical rationale for assessing the impact of childhood sexual abuse on adjunctive subcutaneous esketamine for treatment-resistant depression. Front Psychiatry. 2021;12:608499.","journal-title":"Front Psychiatry"},{"key":"3180_CR142","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s00213-023-06324-8","volume":"240","author":"DS Mathai","year":"2023","unstructured":"Mathai DS, Nayak SM, Yaden DB, Garcia-Romeu A. Reconsidering \u201cdissociation\u201d as a predictor of antidepressant efficacy for esketamine. Psychopharmacology. 2023;240:827\u201336.","journal-title":"Psychopharmacology"},{"key":"3180_CR143","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/ijnp\/pyab084","volume":"25","author":"G Chen","year":"2022","unstructured":"Chen G, Chen L, Zhang Y, Li X, Lane R, Lim P, et al. Relationship between dissociation and antidepressant effects of esketamine nasal spray in patients with treatment-resistant depression. Int J Neuropsychopharmacol. 2022;25:269\u201379.","journal-title":"Int J Neuropsychopharmacol"},{"key":"3180_CR144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-56847-4","volume":"10","author":"QS Li","year":"2020","unstructured":"Li QS, Wajs E, Ochs-Ross R, Singh J, Drevets WC. Genome-wide association study and polygenic risk score analysis of esketamine treatment response. Sci Rep. 2020;10:1\u20139.","journal-title":"Sci Rep"},{"key":"3180_CR145","doi-asserted-by":"publisher","unstructured":"Medeiros GC, Goes FS. Genome-wide association study biomarkers in bipolar disorder. Biomarkers Bipolar Dis. 2022. https:\/\/doi.org\/10.1016\/B978-0-12-821398-8.00016-3.","DOI":"10.1016\/B978-0-12-821398-8.00016-3"},{"key":"3180_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.145","volume":"6","author":"D Rotroff","year":"2016","unstructured":"Rotroff D, Corum D, Motsinger-Reif A, Fiehn O, Bottrel N, Drevets W, et al. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. Trans Psychiatry. 2016;6:e894.","journal-title":"Trans Psychiatry"},{"key":"3180_CR147","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.euroneuro.2019.02.008","volume":"29","author":"M G\u00e4rtner","year":"2019","unstructured":"G\u00e4rtner M, Aust S, Bajbouj M, Fan Y, Wingenfeld K, Otte C, et al. Functional connectivity between prefrontal cortex and subgenual cingulate predicts antidepressant effects of ketamine. Eur Neuropsychopharmacol. 2019;29:501\u20138.","journal-title":"Eur Neuropsychopharmacol"},{"key":"3180_CR148","doi-asserted-by":"crossref","unstructured":"G\u00e4rtner M, de Rover M, V\u00e1clav\u016f L, Scheidegger M, van Osch MJ, Grimm S. Increase in thalamic cerebral blood flow is associated with antidepressant effects of ketamine in major depressive disorder. World J Biol Psychiatry. 2022;23:643\u201352.","DOI":"10.1080\/15622975.2021.2020900"},{"key":"3180_CR149","doi-asserted-by":"crossref","unstructured":"Caliman-Fontes AT, Leal GC, Correia-Melo FS, Paixao CS, Carvalho MS, Jesus-Nunes AP, et al. Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends Psychiatry Psychother. 2023;45:e20210298.","DOI":"10.47626\/2237-6089-2021-0298"},{"key":"3180_CR150","doi-asserted-by":"publisher","first-page":"35305","DOI":"10.4088\/JCP.20r13459","volume":"82","author":"JK Veraart","year":"2021","unstructured":"Veraart JK, Smith-Apeldoorn SY, Spijker J, Kamphuis J, Schoevers RA. Ketamine treatment for depression in patients with a history of psychosis or current psychotic symptoms: a systematic review. J Clin Psychiatry. 2021;82:35305.","journal-title":"J Clin Psychiatry"},{"key":"3180_CR151","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000511348","volume":"90","author":"SL Dubovsky","year":"2021","unstructured":"Dubovsky SL, Ghosh BM, Serotte JC, Cranwell V. Psychotic depression: diagnosis, differential diagnosis, and treatment. Psychother Psychosomatics. 2021;90:160\u201377.","journal-title":"Psychother Psychosomatics"},{"key":"3180_CR152","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1192\/bjp.2017.28","volume":"212","author":"L Van Diermen","year":"2018","unstructured":"Van Diermen L, Van Den Ameele S, Kamperman AM, Sabbe BC, Vermeulen T, Schrijvers D, et al. Prediction of electroconvulsive therapy response and remission in major depression: meta-analysis. Br J Psychiatry. 2018;212:71\u201380.","journal-title":"Br J Psychiatry"},{"key":"3180_CR153","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1176\/appi.ajp.2019.18101123","volume":"176","author":"E Dakwar","year":"2019","unstructured":"Dakwar E, Nunes EV, Hart CL, Foltin RW, Mathew SJ, Carpenter KM, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019;176:923\u201330.","journal-title":"Am J Psychiatry"},{"key":"3180_CR154","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","volume":"177","author":"E Dakwar","year":"2020","unstructured":"Dakwar E, Levin F, Hart CL, Basaraba C, Choi J, Pavlicova M, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177:125\u201333.","journal-title":"Am J Psychiatry"},{"key":"3180_CR155","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa2302399","volume":"388","author":"A Anand","year":"2023","unstructured":"Anand A, Mathew SJ, Sanacora G, Murrough JW, Goes FS, Altinay M, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. N Engl J Med. 2023;388:2315\u201325.","journal-title":"N Engl J Med"},{"key":"3180_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-018-0311-7","volume":"8","author":"W Guo","year":"2018","unstructured":"Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, et al. Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. Trans Psychiatry. 2018;8:1\u20138.","journal-title":"Trans Psychiatry"},{"key":"3180_CR157","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","volume":"175","author":"ST Wilkinson","year":"2018","unstructured":"Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175:150\u20138.","journal-title":"Am J Psychiatry"},{"key":"3180_CR158","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1001\/jamapsychiatry.2021.2500","volume":"78","author":"RC Kessler","year":"2021","unstructured":"Kessler RC, Luedtke A. Pragmatic precision psychiatry\u2014a new direction for optimizing treatment selection. JAMA Psychiatry. 2021;78:1384\u201390.","journal-title":"JAMA Psychiatry"},{"key":"3180_CR159","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2215-0366(17)30272-9","volume":"5","author":"B Short","year":"2018","unstructured":"Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5:65\u201378.","journal-title":"Lancet Psychiatry"},{"key":"3180_CR160","unstructured":"Food and Drug Administration. 2019; USA: Spravato. Food and Drug Administration; 2019."},{"key":"3180_CR161","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.136","volume":"5","author":"C Yang","year":"2015","unstructured":"Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, et al. R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry. 2015;5:e632.","journal-title":"Transl Psychiatry"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03180-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T07:03:58Z","timestamp":1732863838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03180-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":161,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3180"],"URL":"https:\/\/doi.org\/10.1038\/s41398-024-03180-8","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GCM, ID, FSG, CAZ, and TDG have no consulting or grant funding to disclose in the prior 3\u2009years. TDG was supported by NIH\/NIMH R01MH107615 and U.S. Department of Veterans Affairs Merit Awards 1I01BX004062 and 1I01BX006018. Funding for this work was provided in part by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; ZIAMH002857). The contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs, the National Institutes of Health, the Department of Health and Human Services, or the United States Government. TDG is listed as an inventor in patents and patent applications related to the pharmacology and use of a ketamine metabolites, including (2\u2009<i>R<\/i>,6\u2009<i>R<\/i>)-hydroxynorketamine, in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. TDG has assigned his patent rights to the University of Maryland, Baltimore, but will share a percentage of any royalties that may be received by the University of Maryland, Baltimore. CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2\u2009<i>R<\/i>,6\u2009<i>R<\/i>)-hydroxynorketamine, (<i>S<\/i>)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (<i>R,S<\/i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2\u2009<i>R<\/i>,6\u2009<i>R<\/i>)-hydroxynorketamine and (2<i>S<\/i>,6<i>S<\/i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"481"}}